Dupilumab-associated ocular surface disease is characterized by a shift from Th2/Th17 toward Th1/Th17 inflammation. Thormann K, Luthi AS, Deniau F, Heider A, et al. Allergy 2024;79:937-948.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Thormann K, Luthi AS, Deniau F, Heider A, et al. Dupilumab-associated ocular surface disease is characterized by a shift from Th2/Th17 toward Th1/Th17 inflammation. Allergy 2024;79:937-948.
PMID: 38317432